Reparixin (L-lysine salt)

[1]Moriconi A, et al. Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2. J Med Chem. 2007 Aug 23;50(17):3984-4002.|[2]Bertini R, et al. Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2non-competitive allosteric inhibitor. Br J Pharmacol. 2012 Jan;165(2):436-54.|[3]Midgley I, et al. Species differences in the pharmacokinetics and metabolism of reparixin in rat and dog. Xenobiotica. 2006 May;36(5):419-40|[4]Catrina, Anca, et al. METHODS AND COMPOUNDS FOR THE TREATMENT OF BONE LOSS AND/OR PAIN. US 20170105971 A1.|[5]Bertini R, et al. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11791-6.Ann Rheum Dis. 2016 Apr;75(4):721-9.|Biomed Res Int. 2020 Aug 5;2020:4670604.|bioRxiv. 2020 Sep 12;2020.08.25.265561.|Neurobiol Dis. 29 October 2021, 105538.|Patent. US20170105971A1.|Patent. US20170181987A1.|Patent. US20240295544A1.|Adv Sci (Weinh). 2024 Sep 13:e2403430.|Ann Rheum Dis. 2016 Apr;75(4):730-8.|Biochim Biophys Acta. 2017 Jan;1863(1):220-230.|bioRxiv. 2024 Feb 1.|BMC Med. 2022 Feb 8;20(1):55.|Brain Pathol. 2024 Jun 30:e13283.|Cancer Cell Int. 2021 Jul 3;21(1):337.|Cancer Cell. 2023 Apr 10;41(4):693-710.e8.|Cancers (Basel). 2023 Sep 4;15(17):4422.|Cell Biosci. 2019 Jan 3;9:4. |Cell Commun Signal. 2023 Mar 13;21(1):59.|Cell Death Dis. 2017 Jul 13;8(7):e2932.|Cell Mol Gastroenterol Hepatol. 2024 May 7:S2352-345X(24)00105-X.|Cells. 2022 Jun 21;11(13):1986.|Cells. 2022, 11(15), 2402.|EBioMedicine. 2019 May;43:487-500. |FACETS. 2020 Jul.|Front Immunol. 17 October 2022.|Front Immunol. 2021 May 7;12:667177.|Front Immunol. 2018 Sep 12;9:2058.|Gene. 2018 Nov 30;677:149-162.|J Allergy Clin Immunol. 2018 Jun;141(6):2286-2289.e5.|J Cell Mol Med. 2020 Jan;24(2):1588-1598.|J Cell Mol Med. 2020 Nov;24(21):12608-12618.|J Gastroenterol Hepatol. 2018 Feb;33(2):431-442.|J Immunol. 2018 Jul 15;201(2):814-820. |J Mol Cell Biol. 2023 Apr 18;mjad025.|J Mol Med (Berl). 2019 Jan;97(1):25-35. |Johns Hopkins University. Department of Chemical and Biomolecular Engineering. 2016 Dec.|Karolinska Institutet. Dept of Physiology and Pharmacology. 2022 Feb.|Mol Immunol. 2018 Aug 7;101:440-449. |Mol Ther. 2022 Jul 14;S1525-0016(22)00429-4.|Nat Commun. 2017 May 26;8:15584.|Oncogenesis. 2016 Jun 13;5(6):e234. |Oncotarget. 2017 Jul 21;8(36):60210-60222.|Oncotarget. 2018 Aug 24;9(66):32556-32569. |Patent. US20220251222A1.|Research Square Preprint. 2021 Mar.|Research Square Preprint. 2022 Jan.|Sci Adv. 2019 May 8;5(5):eaav7384.|Sci Rep. 2017 Nov 6;7(1):14510. |Stem Cells. 2015 Dec;33(12):3558-68. |University of Michigan. 2018 Oct.|Vet Immunol Immunopathol. 2016 Dec;182:52-58. |Xenotransplantation. 2018 Mar;25(2):e12385.